EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Enterome teamed up with Memorial Sloan Kettering Cancer Center to assess the use of gut microbiome-derived antigens in cancer. Release 

> 4D pharma presented early data from a trial testing bacterium MRx0518 in combination with Merck’s Keytruda. Two of the first six patients had a “clinically relevant response.” Statement 

> Artios Pharma in-licensed a small-molecule ATR inhibitor developed by MD Anderson Cancer Center and ShangPharma. Release 

> Vaccibody presented early data from a phase 1/2a trial of neoantigen cancer vaccine VB10.NEO. Clinical responses were seen in half of the first 14 patients. Statement

> Oxford Drug Design secured £2.2 million ($2.8 million) to fund work to tackle antimicrobial resistance. Release